166 related articles for article (PubMed ID: 25051913)
1. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
Yao ZH; Tian GY; Yang SX; Wan YY; Kang YM; Liu QH; Yao F; Lin DJ
Tumour Biol; 2014 Jul; 35(7):6839-45. PubMed ID: 25051913
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
[TBL] [Abstract][Full Text] [Related]
3. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
4. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
5. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
[TBL] [Abstract][Full Text] [Related]
6. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Hirai F; Seto T; Tagawa T; Takenoyama M; Ichinose Y; Maehara Y
Ann Surg Oncol; 2018 Jun; 25(6):1555-1563. PubMed ID: 29500763
[TBL] [Abstract][Full Text] [Related]
7. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
[TBL] [Abstract][Full Text] [Related]
11. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
12. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
[TBL] [Abstract][Full Text] [Related]
13. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Dome B; Renyi-Vamos F; Oehler R; Hegedus B
Sci Rep; 2017 Nov; 7(1):16456. PubMed ID: 29184132
[TBL] [Abstract][Full Text] [Related]
14. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
Ghanim B; Hoda MA; Klikovits T; Winter MP; Alimohammadi A; Grusch M; Dome B; Arns M; Schenk P; Jakopovic M; Samarzija M; Brcic L; Filipits M; Laszlo V; Klepetko W; Berger W; Hegedus B
Br J Cancer; 2014 Feb; 110(4):984-90. PubMed ID: 24434429
[TBL] [Abstract][Full Text] [Related]
15. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
[No Abstract] [Full Text] [Related]
16. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
[TBL] [Abstract][Full Text] [Related]
17. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
[TBL] [Abstract][Full Text] [Related]
19. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma.
Yao ZH; Tian GY; Wan YY; Kang YM; Guo HS; Liu QH; Lin DJ
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2117-23. PubMed ID: 24149776
[TBL] [Abstract][Full Text] [Related]
20. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
